Does nociceptin play a role in pain disorders in man?

Peptides. 2002 Sep;23(9):1581-7. doi: 10.1016/s0196-9781(02)00101-8.

Abstract

Nociceptin-immunoreactive cellbodies were detected in the human trigeminal ganglion, while no such fibers were identified in the temporal artery or in dermal tissue from the neck region. In four healthy subjects receiving nociceptin into the temporal muscle in an open labeled design no pain was detected. In 10 healthy subjects who received 200pmol of nociceptin into tender non-dominant trapezius muscles in a placebo-controlled, randomized, balanced, and double-blinded design local tenderness increased (P=0.025) while no pain was noted. Thus, the action of nociceptin should be searched for in the trigeminal ganglion and/or in the central nervous system (CNS).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Facial Pain / drug therapy
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Muscles / drug effects
  • Muscles / metabolism
  • Nociceptin
  • Opioid Peptides / metabolism*
  • Pain / metabolism*
  • Pain Threshold / drug effects
  • Placebos
  • Receptors, Opioid / agonists
  • Time Factors
  • Trigeminal Ganglion / drug effects
  • Trigeminal Ganglion / metabolism*
  • Vasodilator Agents / pharmacology

Substances

  • Opioid Peptides
  • Placebos
  • Receptors, Opioid
  • Vasodilator Agents